Objective: Because hormone therapy use benefits sleep, sleep problems may occur after suspension. We tested the effects of short-term hormone therapy suspension on sleep problems.
C urrent guidelines recommend the use of hormone therapy (HT: estrogen with or without progestogen) for short-term relief of menopause-related symptoms. 1 However, it is unclear whether menopausal symptoms return after HT discontinuation. 2<4 Because HT use may alleviate sleep problems, 5<7 a resurgence of sleep problems may occur after HT discontinuation. Sleep problems could have negative implications for immediate daytime functioning 8 and long-term health, such as development of metabolic syndrome. 9 Few studies have examined sleep problems after HT discontinuation, and results have been inconsistent. In a study of 377 women at Kaiser Permanente Northern California who voluntarily attempted to discontinue HT use, 16% reported difficulty sleeping. 2 However, in the Women's Health Initiative (WHI) 3 sleep problems were equally common after discontinuation of estrogen and progestogen therapy (EPT) and placebo. In both cases, women may have been using HT for menopause-related symptoms and prevention. Symptoms experienced after HT suspension in women using HT for prevention purposes may differ from those among women using HT to address menopausal symptoms. 10 Because both of these studies used only a single question to assess sleep problems; a fuller understanding of which aspects of sleep are related to HT discontinuation may assist in specific management.
Previous studies did not provide any detail regarding which charateristics may place women at greater risk for sleep problems after HT discontinuation. For example, EPT may be more effective than estrogen-alone therapy (ET) in helping women sleep because of the additional benefits of progestogens. 11 Therefore, women discontinuing EPT may have a greater resurgence of sleep problems than those discontinuing ET. Women who are younger (and who are likely to have taken HT for fewer years) may benefit more from HT because their sleep problems may be related to the menopausal transition rather than to other age-related factors. 12 Therefore, age and menopausal stage may affect the return of sleep problems after HT discontinuation in younger than in older women. Understanding these more detailed relationships is important for targeted therapies of sleep problems in midlife.
To examine the relationship between short-term HT suspension and sleep problems, we performed a secondary analysis using the data from the Radiological Evaluation and Breast Density (READ) randomized controlled trial. In this trial, women were randomized to continue using HT or suspend for 1 or 2 months before an upcoming mammogram. At the time of the mammogram, women answered questions about sleep problems, allowing us to examine the association between HT suspension and subsequent sleep problems. Our primary hypothesis was that women randomized to HT suspension would have more frequent sleep problems within the 2 months after HT suspension than would women randomized to continue HT. We also tested the following secondary hypotheses: (1) HT suspension would have a stronger effect on the frequency of sleep problems among younger than older women, (2) EPT suspension would result in more frequent sleep problems than suspension of ET, and (3) women who had used HT for a short duration would experience more frequent sleep problems after HT suspension than would women who had used HT for a long duration.
METHODS

Study setting
The details of the READ trial have been described previously. 13, 14 Briefly, we recruited women aged 45 to 80 years from Group Health, an integrated health plan in Western Washington state, to participate in a clinical trial to examine whether brief HT suspension before screening mammography decreased mammographic breast density and the need for additional mammographic imaging. Eligibility for the READ trial was based on mammography history and use of HT within the past 2 years and at the time of study enrollment, in 2004 to 2007. Women were randomly assigned (block random assignment by breast density and HT type) to one of the following HT use groups: continuation, 1-month suspension, or 2-month suspension. Approximately 3 months before their scheduled mammograms, all study participants received a mailed baseline questionnaire and instructions to suspend or continue HT personalized to randomization group. Women also received a follow-up questionnaire to be completed at the time of the mammogram. The institutional review boards at Group Health and the US Department of Defense reviewed and approved this study.
Predictor and outcome assessment
Our main outcome variables, sleep problems, were assessed using a modified General Sleep Disturbance Scale, 15 administered in the follow-up questionnaire. This scale assessed the number of days in the past week (0-7) the respondent had experienced the following: trouble falling asleep, waking while sleeping, waking too early, sleeping poorly, unsatisfied with sleep, waking not rested, too little sleep, using sleep aids, and falling asleep at unscheduled times. The sleep quality index was an average of the number of days the participant experienced each item, excluding using sleep aids. 15 We used each of the individual sleep problems, as well as the sleep quality index, as outcome measures for analysis. Women were excluded if they responded to fewer than 50% of sleep questions.
Age, body mass index, and race were collected from Group HealthYautomated data records. Other characteristics were assessed in the baseline questionnaire, including education, type and duration of HT use, smoking status, alcohol consumption, high blood pressure confirmed by a doctor, bone fracture after age 44 years, or depression. Menopausal symptoms in the past month were also assessed on the baseline questionnaire, using a summary index from the modified Wiklund Menopause Symptom Checklist, 16, 17 which measures average severity scores across a wide range of symptoms including sleep disturbance, mood swings, vaginal bleeding, hot flashes, and night sweats. A separate summary score for the severity of vasomotor symptoms was also computed. A baseline assessment of sleep problems was also collected on the baseline questionnaire.
Statistical analysis
We used generalized linear regression models with robust sandwich variance estimators to test for differences in the frequency of sleep problems (individual items and the sleep quality index) between randomization groups. Because the distribution of the sleep quality index was approximately normal, we used a linear regression to estimate the difference and 95% CIs in the mean sleep quality index score at follow-up for the 1-and 2-month suspension groups relative to the mean for the continuation group. The distributions of the individual sleep items were heavily skewed, so we used a negative binomial model with a log link to calculate incident rate ratios (IRRs) and CIs to compare the randomization groups for trouble falling asleep, waking while sleeping, waking too early, sleeping poorly, unsatisfied with sleep, waking not rested, and too little sleep. Because of the bimodal distribution of the number of days women used sleep aids or fell asleep at unexpected times, we created binary indicators for these two sleep items (any difficulty vs none) and used regression models with a log link and binomial error distribution to calculate relative risks and CIs. Baseline demographic, general health, HT type and duration, menopausal symptoms, and reports of sleep problems did not differ by randomization group. Therefore, we present only unadjusted results.
We tested whether age (split at the sample median age of 58 y), HT type (ET vs EPT), and HT duration before baseline (split at the median duration of use of 13 y) modified the relationships between HT suspension and sleep problems at follow-up. We included an interaction term between each of these stratification variables and an indicator for randomization group. Because the results were similar for the 1-and 2-month suspension groups, we combined these groups into a single suspension group in the models assessing the effect modification. We conducted all analyses in Stata/SE version 10.1 (Stata Corp. LP, College Station, TX).
RESULTS
From the 1,704 randomized participants in the READ trial, 14 226 withdrew before the conclusion of the trial (Fig. 1 ). We excluded 32 participants who did not complete a baseline questionnaire, 28 participants who did not return the follow-up questionnaire, and 13 participants who returned the follow-up questionnaire but responded to fewer than 50% of the sleep questions. The analytic sample (n = 1,405) comprised 518 women randomized to continue HT use, 452 women randomized to 1-month suspension, and 435 women randomized to 2-month suspension. Because nearly 60% of women who did not enroll in the study or withdrew cited an unwillingness to stop HT, 14 our analysis sample largely represents women who were willing to stop HT.
Baseline sociodemographic, health, and menopausal symptom characteristics were similar by randomization group (Table 1) . The average age across all randomization groups was 60 years, and most women in the trial were white, had an educational attainment beyond high school, and did not report a history of high blood pressure, bone fracture, or depression. Approximately half of women in the sample had never smoked, and about 80% of women consumed alcohol a maximum of one to two times per week. Across randomization groups, around 40% of women used EPT, and the median duration of HT use was 13 years ( Table 2) .
At baseline, women reported relatively low severity of menopausal symptoms, with a mean of 1.7 for overall menopausal symptoms and 1.0 for vasomotor symptoms on a scale of 0 to 10, and there were no differences by randomization group (Table 2) . Sleep difficulties reported at baseline also were similar across randomization groups. The sleep item with greatest frequency at baseline was Bwaking while sleeping,[ which happened, on average, 4.5 days per week. Most women did not use sleep aids, and about half reported falling asleep at unscheduled times.
At follow-up, women randomized to the HT suspension groups reported significantly more frequent sleep problems than did women who continued HT use, across nearly all measures of sleep difficulty ( Table 3 ). The mean sleep quality index score was 0.49 (95% CI, 0.29-0.69) and 0.70 (95% CI, 0.50-0.91) higher for the 1-and 2-month suspension groups, respectively, compared with the continuation group. Among the individual sleep items, the greatest differences between the women randomized to suspend HT compared with the women randomized to continue HT were for the outcomes of trouble falling asleep, sleeping poorly, and waking too early. Compared with the continuation group, the 2-month suspension group reported 46% more days with trouble falling asleep (IRR, 1.46; 95% CI, 1.24-1.73), 46% days sleeping poorly (IRR, 1.46; 95% CI, 1.31-1.62) more, and 31% more days waking too early (IRR, 1.31; 95% CI, 1.16-1.48). The effects of 1-month suspension were less pronounced but were statistically significant. Similarly, the differences in the sleep index and the estimated relative incidence rates for waking while sleeping, being unsatisfied with sleep, not rested when woke up, and too little sleep were stronger for the 2-month than 1-month suspension group. The frequency of use of sleep aids and falling asleep at unscheduled times did not vary according to randomization group. Approximately one third of all women used sleep aids, and approximately half of all participants fell asleep at unscheduled times in the past week.
In secondary analyses to assess effect modification, the relationships between HT suspension and sleep problems did not differ significantly by age, HT type, or HT duration. The estimated effects of HT suspension on the overall sleep quality index score at follow-up within strata of these potential effect modifiers are summarized in Table 4 (data for other sleep items not shown). Although the point estimates suggest that the effect of HT suspension on the frequency of sleep problems may be greater in older women and women who used EPT, these differences were not statistically significant.
DISCUSSION
In a large randomized controlled trial of short-term HT suspension, women randomized to 1-or 2-month suspension reported more frequent sleep problems than did women randomized to continue HT use. Although differences between groups were moderate, HT suspension was associated with higher frequency in trouble falling asleep, waking while sleeping, waking too early, sleeping poorly, being unsatisfied with sleep, not rested when waking, and too little sleep. The aggregate effect of pervasive moderate sleep problems over time may be substantial.
Our results are consistent with those of a previous small study of voluntary HT suspension at Kaiser Permanente Northern California, which found a moderate increase in sleep problems after HT suspension after a median follow-up of 5.7 months. 2 However, the WHI did not detect more sleep problems after HT discontinuation among women randomized to HT than those randomized to placebo. 3 Differences in follow-up time and study population characteristics may explain inconsistencies between our results and those of the WHI. First, the follow-up period in the READ trial was only a few months compared with 8 to 12 months in the other trial. It is possible that sleep problems dissipate with time after HT discontinuation, because both the READ trial and the previous observational study with abbreviated follow-up found moderate increases in sleep problems after HT suspension. Second, more than 80% of women in the READ trial were taking HT for symptom management. 14 Women in the WHI were randomized to HT for chronic disease prevention, and only 18% reported sleeping difficulty at baseline. 3 Because a greater proportion of women in the WHI may not have had sleep problems before taking HT, one would not anticipate a worsening of symptoms after HT suspension. 10 The high level of follow-up sleep problems in the READ trial may have been related to a return of vasomotor symp-toms. Previous studies of menopausal symptoms after HT discontinuation have found vasomotor symptom resurgence to be a frequent problem within 1 year, although the association with sleep was not studied. 2, 3, 18 Increased vasomotor symptoms after HT suspension may mediate the relationships between HT suspension and subsequent sleep problems, 12 or a common underlying factor such as sympathetic activation may influence both vasomotor symptoms and sleep problems. 19 Adjustment for a resurgence of menopausal symptoms in our regression models would lead to a model that would be difficult to interpret. We explored the possible relationship between vasomotor symptoms and sleep problems by comparing changes in vasomotor symptom scores and sleep quality index scores from baseline to follow-up. Overall, women who experienced a significant resurgence of vasomotor symptoms at follow-up, defined as having a change from baseline to in the highest quarter, were more likely to also experience increased sleep quality index scores.
Another explanation for the higher frequency of sleep problems after HT suspension that we observed may relate to the effect of progesterone and estrogen on sleep in humans. Progesterone has an overall sedative effect, 11 and exogenous estrogen has been shown to decrease latency to sleep onset, 20,21 decrease awakening after sleep onset, 12, 20 and increase total sleep time. 21 Exogenous estrogen may also benefit sleep by reducing stress reactivity. 22 Although estrogen We used a W 2 test for binary exposure variables, a Kruskal-Wallis test for ordered categorical exposure variables, and an analysis of variance for continuous exposure variables. and progesterone may directly influence specific sleep processes, 23 sex steroids may also influence sleep through effects on general central nervous system arousal 24 and/or thermoregulation. 12 Although our sample represents women willing to suspend HT, the use of a randomized controlled trial was a strength of the analysis. The population-based approach of random sampling from among the midlife women in Group Health who used HT and were due for a mammogram lessened sampling biases. For example, recruiting only women at the time of a treatment visit for menopausal symptoms might result in sampling women with more severe symptoms.
The major limitation of our trial was that women were not blinded to HT suspension. Approximately 51% of recruited women did not enroll, with around half of these women citing an unwillingness to stop HT as the reason for not participating. However, nonparticipants had similar key baseline characteristics as participants. 14 Nonparticipants may have been more concerned about menopausal symptom resurgence than participants. 14, 25, 26 a factor we did not measure. In addition, around 18% of women randomized to HT suspension dropped out before the completion of the trial. These women probably restarted HT use because of the return of symptoms. Therefore, our results are probably conservative estimates. Given that women will have different propensities for discontinuing HT use, our findings only described sleep problems after suspension among those willing to stop HT. A small proportion of women (9%) could not adhere to HT suspension after randomization. However, excluding nonadherent women (n = 82) and women who did not respond to the adherence question (n = 13) did not change our results. We were unable to record whether women used medications for other reasons that might have improved sleep, including selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors. 27 However, insomnia symptoms are also common adverse effects of selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors. Our study did not capture any laboratory measures of sleep, which may have different associations with HT suspension than self-reported sleep measures, 28, 29 or severity of sleep problems.
Several characteristics of our sample may have masked differences in the relationships between HT suspension and sleep problems by age, HT type, or HT duration. Because We combined 1-and 2-month suspension groups into one group. eligible women must have been using HT for 2 years before recruitment, our sample could not have detected differences related to recent initiation of HT. Similarly, 75% of the women in our sample were 53 years and older, which may have obscured any differences related to younger age, in particular, the menopausal transition.
CONCLUSIONS
In conclusion, in a group of women willing to suspend HT use for a short term, women randomized to suspend HT had more frequent problems across sleep domains measured within a few months after suspension, compared with women randomized to continue HT. Women who choose to discontinue HT use may need specific assistance to manage sleep problems after HT discontinuation.
